ClinicalTrials.gg
CompletedNCT03522298Updated Mar 24, 2025Results posted

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

A Phase 2 interventional study of Paxalisib (GDC-0084) in Glioblastoma, Adult, sponsored by Kazia Therapeutics Limited. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Kazia Therapeutics Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
601st of 1,155
30 · median 33
Started
2018
with 71 others
Phase 2
396 of 1,302
37 open now
Registered
849th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 601st largest by enrollment of the 1,155 interventional ones that give a count, is one of 72 that started in 2018, is one of 396 in phase 2, and was the 849th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

This protocol has a 2-part design:

This phase 2 study is an open-label, multicenter, dose-escalation and expansion study to assess the safety, tolerability, recommended phase 2 dose (RP2D), pharmacokinetics (PK) and clinical activity of paxalisib in patients with newly-diagnosed glioblastoma (GBM) with unmethylated MGMT promoter status as adjuvant therapy following surgical resection and initial chemoradiation with temozolomide (TMZ).

Read the detailed description

Stage 1 Dose-Escalation and Maximum Tolerated Dose The dose-escalation portion of the study (Stage 1) will use a standard "3 + 3" design to determine the MTD for QD dosing.

Approximately 6 - 12 patients with newly diagnosed GBM will be enrolled in Stage 1.

The MTD for QD dosing will be determined. The initial dose level for QD dosing will be 60 mg (Dose Level 0). This dose is based on the phase 1 findings outlined in the rationale in the protocol, adding 1 dose level to test for a potential MTD increase.

Dose-escalation will occur in Stage 1:

  • The initial dose (Dose Level 0) for QD MTD determination in Step 1 will be 60 mg. Dose levels will increase in 15 mg steps;
  • The dose-escalation portion of the study (Stage 1) will use a standard "3 + 3" design to assess the safety, tolerability, and PK of paxalisib administered orally in 28-day cycles;

Decisions regarding dose-escalation and selection will be made by a Cohort Review Committee (CRC).

All AEs, including DLTs, will be reported, with severity assessed according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.

After determination of the MTD, patients continue to receive their protocol-assigned dose levels of paxalisib until progression of their disease or an unacceptable toxicity, whichever occurs first.

Stage 2 Expansion stage (2) of the study will be a two-arm, randomized, open-label expansion study to further characterize the safety, tolerability and PK of paxalisib as well as to provide a preliminary assessment of single-agent activity of paxalisib in patients with GBM. Approximately 20 patients will be enrolled in the expansion cohort in 2 treatment arms (10 per am) to examine the PK of paxalisib in fed and fasted-conditions, according to the defined study eligibility criteria.

Stage 2 of the study will be initiated with recruitment of new patients as soon as the MTD has been determined.

Patients enrolled in Stage 2 may continue the study at the dose allocated until disease progression or unacceptable toxicity.

03

Conditions studied

  • Glioblastoma, Adult

Browse trials for

Keywords

  • newly diagnosed
  • unmethylated O6 methylguanine-methyltransferase (MGMT) promoter status
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all the following inclusion criteria to be eligible for enrollment into the study:

  1. Age ≥ 18 years;
  2. > 12 weeks;
  3. Present with confirmed intracranial (supratentorial) unmethylated MGMT promotor status GBM (WHO Grade lV astrocytoma) with a MGMT status that has been confirmed by validated PCR or validated alternate genomic analysis;
  4. Have undergone maximal surgical resection of their tumor and within 6 weeks of surgery received initial treatment with XRT/TMZ which consisted of XRT by external beam to a partial brain field in daily fractions of 2.0 Gray (Gy), to a planned total dose to the tumor of 60.0 Gy, in conjunction with TMZ oral QD 75 mg/m2 in accordance with the Stupp regimen;
  5. Must have , according to RANO criteria for inclusion in the expansion cohort. Patients with non-measurable disease can be included in the dose-escalation cohorts;
  6. ≥ 70;
  7. Cranial magnetic resonance imaging (MRI) must have been performed within 7 days prior to or on the day of the Randomization/Week 1 Visit;
  8. Stable or decreasing dose within 7 days prior to the first dose;
  9. Adequate bone marrow/hematological function within 7 days prior to Day 1;
  10. Adequate liver and renal function within 14 days prior to Day 1;
  11. (INR) or prothrombin time (PT) (secs) and activated partial thromboplastin time (aPTT) within 7 days prior to randomization:
  12. Patients must be willing to forego other drug therapy against the tumor while enrolled in the study.

Exclusion criteria

Exclusion Criteria:

  1. Previous radiotherapy to the brain or cytotoxic drug therapy (including Gliadel® wafers) in addition to the required postoperative radiation plus TMZ, non-cytotoxic drug therapy, or experimental drug therapy directed against the brain tumor prior to this regimen, will be excluded. Patients may have received or be receiving , analgesics, and other drugs to treat symptoms or prevent complications but the dose must be stable at treatment start. NOTE: 5 aminolevulinic acid-mediated photodynamic therapy administered prior to surgery to aid in optimal surgical resection is not considered a chemotherapy agent;
  2. Any prior or anticipated concomitant treatment involving a medical device (such as Optune®) applying tumor treating fields (TTF);
  3. time of ≥ 470 msec;
  4. Undetermined/indeterminate MGMT status;
  5. Diabetic patients; prediabetic patients treated with metformin;
  6. Use of any inducing or inhibiting agents;
  7. Significant medical illnesses;
  8. Women who are pregnant or who are lactating;
  9. Diagnosed with infratentorial GBM, a tumor outside of brain or gliomatosis cerebri;
  10. Evidence of recent hemorrhage on postoperative MRI of the brain;
  11. Any previous ; except for adequately controlled limited basal cell carcinoma of the skin, squamous carcinoma of the skin or carcinoma in situ of the cervix, or one which has been absent for ≥3 years;
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Dose Escalation and Expansion Cohorts

    This is an open-label study. Patients in Stage 1 will be enrolled and sequentially assigned to a dose cohort. The initial cohort will receive an oral dose of 60 mg paxalisib QD (4 x 15 mg capsules). Patients of future dose cohorts will receive paxalisib at increasing levels with 15 mg steps until a dose-limiting toxicity occurs (DLT) occurs. The dose level where \<1/3 of the patients exhibit a DLT will be determined the Maximum Tolerated Dose (MTD). In stage 1, dose escalation will occur for QD dosing. In stage 2, the expansion phase, patients will receive doses of oral paxalisib at the MTD in stage 1, until disease progression or an unacceptable toxicity, whichever occurs first. Patients will be randomized in a 1:1 ratio to fed or fasted schedules.

    Drug: Paxalisib (GDC-0084)

Interventions

  • Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)

    A DLT was defined as a Grade 3 or 4 toxicity occurring within the DLT assessment window and assessed to be probably or possibly related to paxalisib. DLTs were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. CTCAE Grade 3 is a severe adverse event (AE) and Grade 4 is a life-threatening or disabling AE. DLTs were collected to determine the maximum tolerated dose (MTD), which was defined as the dose level below the dose at which less than 33% of participants experienced a DLT.

    Time frame: Cycle 1, Days 1-28

Secondary outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAEs)

    The toxicity assessments were made according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. A TEAE is any AE occurring or worsening on/after the first study drug dose and within 28 days after the last dose date. The number of participants with Grade 1 to 5 TEAEs are reported here. Specific Adverse Event terms are provided in the Adverse Event module

    Time frame: 24 months

  2. Incidence of Serious Adverse Events (SAEs)

    An SAE is any AE that meets one or more of the following: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; requires intervention to prevent permanent impairment or damage. Specific AE terms are provided in the Adverse Event module

    Time frame: 24 months

  3. Incidence of Treatment-emergent Grade 3/4 Treatment Emergent Adverse Events

    Treatment emergent Adverse Events were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. CTCAE Grade 3 is a severe adverse event (AE) and Grade 4 is a life-threatening or disabling AE. Participants are counted at the highest grade TEAE that they experienced.

    Time frame: 24 months

  4. Number of Participants Who Experienced a Change in Electrocardiogram (ECG) Parameter QTc

    A change in ECG parameter QTc was defined as an increase of QTc to a value ≥ 500 msec or a change from baseline of at least 60 msec.

    Time frame: 24 months

  5. Number of Participants Who Experienced a Change Left Ventricular Ejection Fraction

    A change in left ventricular ejection fraction (LVEF) was defined as a reduction in LVEF to a value of ≤ 45% from baseline.

    Time frame: 24 months

  6. Progression-free Survival Interval Using Using mRANO Criteria/Investigator Review.

    Progression-free survival is defined as the duration of time from start of treatment to time of progression or death, whichever comes first.

    Time frame: 24 months

  7. Overall Survival Using RANO Criteria.

    Overall survival is defined as the duration of time from the first day of study treatment until the date of death.

    Time frame: 24 months

Other outcomes

  1. Pharmacokinetics of Paxalisib as Area Under the Curve From Time 0 to Last Measurable Time Point (AUC0-last) and/or Area Under the Curve From Time 0 to Infinity (AUC0-inf).

    Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. Samples were obtained: prior to the initial dose on Cycle 1 Day 1 and then at 30 minutes, and at 1, 2, 3, 4, 6 8 and 24 hours post dose.

    Time frame: 24 hours

  2. Maximum Observed Plasma Concentration of Paxalisib (Cmax)

    Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. Samples were obtained: prior to the initial dose on Cycle 1 Day 1 and then at 30 minutes, and at 1, 2, 3, 4, 6 8 and 24 hours post dose.

    Time frame: 24 hours

  3. Pharmacokinetics of Paxalisib as Time to Reach Cmax (Tmax).

    Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. Samples were obtained: prior to the initial dose on Cycle 1 Day 1 and then at 30 minutes, and at 1, 2, 3, 4, 6 8 and 24 hours post dose.

    Time frame: 24 hours

  4. Change in FDG-PET Uptake in Response to Paxalisib in Patients With Measurable Disease.

    FDG-PET imaging was obtained using a stand-alone PET or combined PET/computed tomography (CT) scanner, or hybrid PET/MRI systems and the and mean FDG-PET standard uptake value quantified

    Time frame: Cycle 1, Day 3

  5. Change in FDG-PET Uptake in Response to Paxalisib in Patients With Measurable Disease

    FDG-PET imaging was obtained using a stand-alone PET or combined PET/computed tomography (CT) scanner, or hybrid PET/MRI systems and the and mean FDG-PET standard uptake value quantified

    Time frame: Cycle 1, Day 7

  6. Disease Control Rate.

    Response to treatment was assessed by MRI using the response assessment in neuro-oncology (RANO) criteria based on the assessment of the MRI scan and clinical features. The DCR is defined as the proportion of patients achieving a confirmed best overall response of complete response (CR; disappearance of all enhancing disease, clinically stable/improved), partial response (PR; 50% or more decrease in measurable enhancing lesions, clinically stable/improved), or stable disease (SD, does not qualify for CR or PR, does not qualify for disease progression, clinically stable). To be assigned a status of CR, PR or SD patients need to have two consecutive assessments of CR, PR or SD. To be assigned a best overall response of SD patients must have a minimum duration of SD of at least 6 weeks.

    Time frame: 24 months

07

Results

Posted Mar 24, 2025

Participant flow

Open-label, multicenter dose-escalation study with expansion. This study comprised 2 stages, Stage 1 (dose escalation) and Stage 2 (dose expansion and fed/fasted investigation)

Participant flow — Overall Study
MilestoneDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Started361011
Completed0000
Not completed361011
Withdrew: Adverse event1001
Withdrew: Death2488
Withdrew: Patient decision0222

Outcome measures

PrimaryNumber of Participants Who Experienced Dose-Limiting Toxicities (DLTs)

A DLT was defined as a Grade 3 or 4 toxicity occurring within the DLT assessment window and assessed to be probably or possibly related to paxalisib. DLTs were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. CTCAE Grade 3 is a severe adverse event (AE) and Grade 4 is a life-threatening or disabling AE. DLTs were collected to determine the maximum tolerated dose (MTD), which was defined as the dose level below the dose at which less than 33% of participants experienced a DLT.

Time frame:
Cycle 1, Days 1-28
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
ParticipantsDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mg
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)02
SecondaryIncidence of Treatment-emergent Adverse Events (TEAEs)

The toxicity assessments were made according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. A TEAE is any AE occurring or worsening on/after the first study drug dose and within 28 days after the last dose date. The number of participants with Grade 1 to 5 TEAEs are reported here. Specific Adverse Event terms are provided in the Adverse Event module

Time frame:
24 months
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Adverse Events (TEAEs)
ParticipantsDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Incidence of Treatment-emergent Adverse Events (TEAEs)361011
SecondaryIncidence of Serious Adverse Events (SAEs)

An SAE is any AE that meets one or more of the following: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; requires intervention to prevent permanent impairment or damage. Specific AE terms are provided in the Adverse Event module

Time frame:
24 months
Reported as:
Count of participants · Participants
Incidence of Serious Adverse Events (SAEs)
ParticipantsDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Incidence of Serious Adverse Events (SAEs)2565
SecondaryIncidence of Treatment-emergent Grade 3/4 Treatment Emergent Adverse Events

Treatment emergent Adverse Events were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. CTCAE Grade 3 is a severe adverse event (AE) and Grade 4 is a life-threatening or disabling AE. Participants are counted at the highest grade TEAE that they experienced.

Time frame:
24 months
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Grade 3/4 Treatment Emergent Adverse Events
ParticipantsDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Grade 1 or 20010
Grade 333910
Grade 40301
SecondaryNumber of Participants Who Experienced a Change in Electrocardiogram (ECG) Parameter QTc

A change in ECG parameter QTc was defined as an increase of QTc to a value ≥ 500 msec or a change from baseline of at least 60 msec.

Time frame:
24 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Change in Electrocardiogram (ECG) Parameter QTc
ParticipantsDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Number of Participants Who Experienced a Change in Electrocardiogram (ECG) Parameter QTc0000
SecondaryNumber of Participants Who Experienced a Change Left Ventricular Ejection Fraction

A change in left ventricular ejection fraction (LVEF) was defined as a reduction in LVEF to a value of ≤ 45% from baseline.

Time frame:
24 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Change Left Ventricular Ejection Fraction
ParticipantsDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Number of Participants Who Experienced a Change Left Ventricular Ejection Fraction0001
SecondaryProgression-free Survival Interval Using Using mRANO Criteria/Investigator Review.

Progression-free survival is defined as the duration of time from start of treatment to time of progression or death, whichever comes first.

Time frame:
24 months
Reported as:
Median · Months
Progression-free Survival Interval Using Using mRANO Criteria/Investigator Review.
MonthsDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Progression-free Survival Interval Using Using mRANO Criteria/Investigator Review.14.5 (3.3 to 25.7)4.7 (1.8 to 27.4)7.0 (1.0 to 13.2)5.5 (2.0 to 11.8)
SecondaryOverall Survival Using RANO Criteria.

Overall survival is defined as the duration of time from the first day of study treatment until the date of death.

Time frame:
24 months
Reported as:
Median · Months
Overall Survival Using RANO Criteria.
MonthsDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Overall Survival Using RANO Criteria.20.1 (14.4 to 25.7)11.8 (4.4 to 37.5)12.0 (7.6 to 17.6)9.8 (2.0 to 15.1)
Other pre-specifiedPharmacokinetics of Paxalisib as Area Under the Curve From Time 0 to Last Measurable Time Point (AUC0-last) and/or Area Under the Curve From Time 0 to Infinity (AUC0-inf).

Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. Samples were obtained: prior to the initial dose on Cycle 1 Day 1 and then at 30 minutes, and at 1, 2, 3, 4, 6 8 and 24 hours post dose.

Time frame:
24 hours
Reported as:
Geometric mean · ng/mL*h
Pharmacokinetics of Paxalisib as Area Under the Curve From Time 0 to Last Measurable Time Point (AUC0-last) and/or Area Under the Curve From Time 0 to Infinity (AUC0-inf).
ng/mL*hDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Pharmacokinetics of Paxalisib as Area Under the Curve From Time 0 to Last Measurable Time Point (AUC0-last) and/or Area Under the Curve From Time 0 to Infinity (AUC0-inf).1180 ± 36.61120 ± 91.42190 ± 34.51640 ± 67.1
Other pre-specifiedMaximum Observed Plasma Concentration of Paxalisib (Cmax)

Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. Samples were obtained: prior to the initial dose on Cycle 1 Day 1 and then at 30 minutes, and at 1, 2, 3, 4, 6 8 and 24 hours post dose.

Time frame:
24 hours
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration of Paxalisib (Cmax)
ng/mLDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Maximum Observed Plasma Concentration of Paxalisib (Cmax)174 ± 108118 ± 67.4176 ± 24.2114 ± 44.2
Other pre-specifiedPharmacokinetics of Paxalisib as Time to Reach Cmax (Tmax).

Blood samples were obtained and plasma concentrations were determined using a validated high-pressure liquid chromatography method. Samples were obtained: prior to the initial dose on Cycle 1 Day 1 and then at 30 minutes, and at 1, 2, 3, 4, 6 8 and 24 hours post dose.

Time frame:
24 hours
Reported as:
Median · Hours
Pharmacokinetics of Paxalisib as Time to Reach Cmax (Tmax).
HoursDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Pharmacokinetics of Paxalisib as Time to Reach Cmax (Tmax).3.00 (2.00 to 5.42)2.50 (1.95 to 4.00)4.00 (2.80 to 8.00)3.93 (3.00 to 8.00)
Other pre-specifiedChange in FDG-PET Uptake in Response to Paxalisib in Patients With Measurable Disease.

FDG-PET imaging was obtained using a stand-alone PET or combined PET/computed tomography (CT) scanner, or hybrid PET/MRI systems and the and mean FDG-PET standard uptake value quantified

Time frame:
Cycle 1, Day 3
Reported as:
Mean · standardized uptake value
Change in FDG-PET Uptake in Response to Paxalisib in Patients With Measurable Disease.
standardized uptake valueExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Change in FDG-PET Uptake in Response to Paxalisib in Patients With Measurable Disease.0.036 ± 0.7523-0.442 ± 0.3517
Other pre-specifiedChange in FDG-PET Uptake in Response to Paxalisib in Patients With Measurable Disease

FDG-PET imaging was obtained using a stand-alone PET or combined PET/computed tomography (CT) scanner, or hybrid PET/MRI systems and the and mean FDG-PET standard uptake value quantified

Time frame:
Cycle 1, Day 7
Reported as:
Mean · standardized uptake value
Change in FDG-PET Uptake in Response to Paxalisib in Patients With Measurable Disease
standardized uptake valueExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Change in FDG-PET Uptake in Response to Paxalisib in Patients With Measurable Disease-0.366 ± 1.1814-0.432 ± 0.5963
Other pre-specifiedDisease Control Rate.

Response to treatment was assessed by MRI using the response assessment in neuro-oncology (RANO) criteria based on the assessment of the MRI scan and clinical features. The DCR is defined as the proportion of patients achieving a confirmed best overall response of complete response (CR; disappearance of all enhancing disease, clinically stable/improved), partial response (PR; 50% or more decrease in measurable enhancing lesions, clinically stable/improved), or stable disease (SD, does not qualify for CR or PR, does not qualify for disease progression, clinically stable). To be assigned a status of CR, PR or SD patients need to have two consecutive assessments of CR, PR or SD. To be assigned a best overall response of SD patients must have a minimum duration of SD of at least 6 weeks.

Time frame:
24 months
Reported as:
Count of participants · Participants
Disease Control Rate.
ParticipantsDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
Disease Control Rate.3489

Adverse events

Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose-escalating Cohort 1: Paxalisib 60mg2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Dose-escalating Cohort 2: Paxalisib 75 mg4/6 (66.7%)5/6 (83.3%)6/6 (100%)
Expansion Cohort: Paxalisib 60mg (Fed)8/10 (80%)6/10 (60%)10/10 (100%)
Expansion Cohort: Paxalisib 60mg (Fasted)8/11 (72.7%)5/11 (45.5%)11/11 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
FatigueGeneral disorders1/30/60/101/11
DehydrationMetabolism and nutrition disorders1/30/61/100/11
HyperglycaemiaMetabolism and nutrition disorders0/32/61/101/11
Acute kidney injuryRenal and urinary disorders1/30/60/100/11
Dermatitis exfoliativeSkin and subcutaneous tissue disorders1/30/60/100/11
PneumoniaInfections and infestations0/30/62/100/11
StomatitisGastrointestinal disorders0/31/61/100/11
confusional statePsychiatric disorders0/31/61/100/11
Status epilepticusNervous system disorders0/31/60/100/11
Posterior reversible encephalopathy syndromeNervous system disorders0/31/60/100/11
Most frequent other events
Showing 10 of 40
Most frequent other events
EventDose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)
FatigueGeneral disorders3/34/66/109/11
HyperglycaemiaMetabolism and nutrition disorders1/35/63/104/11
NauseaGastrointestinal disorders2/32/64/104/11
VomitingGastrointestinal disorders2/31/61/103/11
ConstipationGastrointestinal disorders2/30/60/101/11
DehydrationMetabolism and nutrition disorders2/31/64/102/11
Platelet count decreasedInvestigations2/34/62/101/11
StomatitisGastrointestinal disorders1/33/66/104/11
Decreased appetiteMetabolism and nutrition disorders1/32/65/106/11
DiarrhoeaGastrointestinal disorders0/33/62/105/11

Baseline characteristics

ITT population The intent-to-treat (ITT) population consisted of all patients who were enrolled in the study, whether in Stage 1 or Stage 2.

Age, Continuous
Age, Continuous(years)Dose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)Total
Mean68 ± 15.7256 ± 9.3056 ± 12.5159.5 ± 9.4658.5 ± 11.16
Sex: Female, Male
Sex: Female, Male(Participants)Dose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)Total
Female02349
Male347721
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)Total
Hispanic or Latino01012
Not Hispanic or Latino35101028
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)Total
American Indian or Alaska Native00000
Asian01102
Native Hawaiian or Other Pacific Islander00000
Black or African American10001
White2491025
More than one race00000
Unknown or Not Reported01012
Region of Enrollment
Region of Enrollment(participants)Dose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)Total
United States36101130
Time since diagnosis
Time since diagnosis(months)Dose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)Total
Mean3.68 ± 0.5534.33 ± 1.1373.64 ± 0.3583.56 ± 0.3183.75 ± 0.637
Type of surgery
Type of surgery(Participants)Dose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)Total
Biopsy (Patients later had a complete resection)00112
Complete resection249722
Partial resection12025
Other (stereotactic biopsy)00011
Histological diagnosis
Histological diagnosis(Participants)Dose-escalating Cohort 1: Paxalisib 60mgDose-escalating Cohort 2: Paxalisib 75 mgExpansion Cohort: Paxalisib 60mg (Fed)Expansion Cohort: Paxalisib 60mg (Fasted)Total
Count of participants36101130

1 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • University of California Los Angeles - Jonsson Comprehensive Cancer Center
    Los Angeles, California 90095, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • University of Oklahoma Health Sciences Center (Stephenson Cancer Center)
    Oklahoma City, Oklahoma 73104, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Mar 2023, 58 months.

Results were first posted in Mar 2025, 1 year 11 months after primary completion.

Of 51 industry-sponsored phase 2 interventional studies under Glioblastoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 58. This study's 58 months is above that.

Counting every sponsor, half of 249 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2018
First posted
May 11, 2018
StartActual
May 15, 2018
Primary completionActual
Mar 30, 2023
CompletionActual
Mar 30, 2023
Results first posted
Mar 24, 2025
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03522298
Lead sponsor
Kazia Therapeutics Limited
Responsible party
Sponsor
First posted
May 11, 2018
Start date
May 15, 2018
Primary completion
Mar 30, 2023
Completion
Mar 30, 2023
Results posted
Mar 24, 2025
Last update
Mar 24, 2025

Study contacts

James Garner, MD
study director · Kazia Therapeutics Limited

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GDC-0084

Start the discussion